Blueprint Medicines Corp. started a rolling submission for U.S Food and Drug Administration approval of the lung cancer treatment pralsetinib.
The Cambridge, Mass.-based company has begun the new drug application process for the oral medicine as a treatment for non-small cell lung cancer patients with a mutation in the RET gene. The gene's mutations have been identified in several types of cancer, including lung cancer.
Pralsetinib was submitted to the FDA after early-stage trial results showed that 61% of the lung cancer patients with this gene mutation responded to the treatment.
Blueprint expects to complete the submission in the first quarter of 2020.
The company also intends to submit pralsetinib to the FDA in the second quarter of 2020 for treating a type of thyroid cancer.